Track 08 of 9
Health Equity in Obesity Care
Disparities, stigma and access to evidence-based care.
The promise of GLP-1 therapeutics has thrown disparities into sharp relief: list prices exceed $1,000 per month, Medicare Part D coverage remains restricted to cardiovascular and MASH indications, and Black, Hispanic, and rural patients are underrepresented in both clinical trials and prescribing. The track will examine weight stigma in clinical encounters (the Rudd Center evidence base), patient-first language, structural racism and the social determinants of obesity, and policy levers including the Treat and Reduce Obesity Act. Sessions will also address culturally tailored interventions and community-based participatory research.
Focus areas
- Weight stigma in clinical care and patient-first language
- Race, ethnicity and rural disparities in GLP-1 prescribing
- Medicare Part D, Treat and Reduce Obesity Act and policy reform
- Social determinants and structural drivers of obesity
- Culturally tailored lifestyle and behavioral interventions
- Community-based participatory research and trust-building
- Insurance prior authorization and step-therapy reform